摘要:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译:使用下式的CCR5拮抗剂或其药学上可接受的盐,其中R是任选取代的苯基,吡啶基,噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基,取代的杂芳基,萘基,芴基,二苯基甲基或任选取代的苯基或杂芳基 - 烷基; R 3是氢,烷基,烷氧基烷基,环烷基,环烷基烷基或任选取代的苯基,苯基烷基,萘基,萘基烷基,杂芳基或杂芳基烷基; R 4,R 5和R 7是氢或烷基; R 6是氢,烷基或链烯基; 公开了用于治疗HIV,实体器官移植排斥,移植物抗宿主病,关节炎,类风湿性关节炎,炎症性肠病,特应性皮炎,牛皮癣,哮喘,过敏或多发性硬化的新型化合物,以及包含它们的药物组合物 ,以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。
摘要:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译:使用下式的CCR5拮抗剂或其药学上可接受的盐,其中R是任选取代的苯基,吡啶基,噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基,取代的杂芳基,芴基,二苯甲基或任选取代的苯基或杂芳基烷基; R 3是氢,烷基,烷氧基烷基,环烷基,环烷基烷基或任选取代的苯基,苯基烷基,萘基,萘基烷基,杂芳基或杂芳基烷基; R 4,R 5和R 7是氢或烷基; R 6是氢,烷基或链烯基; 公开了用于治疗HIV,实体器官移植排斥,移植物抗宿主病,关节炎,类风湿性关节炎,炎症性肠病,特应性皮炎,牛皮癣,哮喘,过敏或多发性硬化的新型化合物,以及包含它们的药物组合物 ,以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。
摘要:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译:使用下式的CCR5拮抗剂或其药学上可接受的盐,其中R是任选取代的苯基,吡啶基,噻吩基或萘基; R1是氢或烷基; R 2是取代的苯基,取代的杂芳基,芴基,二苯基甲基或任选取代的苯基或杂芳基 - 烷基; R 3是氢,烷基,烷氧基烷基,环烷基,环烷基烷基或任选取代的苯基,苯基烷基,萘基,萘基烷基,杂芳基或杂芳基烷基; R4,R5和R7是氢或烷基; R6是氢,烷基或烯基; 公开了用于治疗HIV,实体器官移植排斥,移植物抗宿主病,关节炎,类风湿性关节炎,炎症性肠病,特应性皮炎,牛皮癣,哮喘,过敏或多发性硬化的新型化合物,以及包含它们的药物组合物 ,以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。
摘要:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v, host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译:使用下式的CCR5拮抗剂或其药学上可接受的盐,其中R是任选取代的苯基,吡啶基,噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基,取代的杂芳基,萘基,芴基, 苯基烷基,萘基,萘基烷基,杂芳基或杂芳基烷基; R 4,R 5,R 5和R 5独立地选自氢,烷基,烷氧基烷基,环烷基,环烷基烷基或任选取代的苯基, R 7为氢或烷基; R 6为氢,烷基或烯基;用于治疗HIV,实体器官移植排斥,移植物v,宿主病,关节炎,类风湿性关节炎,炎性肠病,特应性皮炎, 公开了牛皮癣,哮喘,过敏或多发性硬化,以及新化合物,包含它们的药物组合物,以及本发明的CCR5拮抗剂与用于治疗 可用于治疗炎性疾病的HIV或药物。
摘要:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein X is —C(R13)2—, —C(R13)(R19)—, —C(O)—, —O—, —NH—, —N(alkyl)—, R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is H, alkyl or alkenyl; R2 is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R3 is optionally substituted phenyl, heteroaryl or naphthyl; R4 is H, alkyl, fluoro-alkyl, cyclopropylmethyl, —CH2CH2OH, —CH2CH2—O-alkyl, —CH2C(O)—O-alkyl, —CH2C(O)NH2, —CH2C(O)—NHalkyl or —CH2C(O)—N(alkyl)2; R19 is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R5, R13, R14, R15 and R16 are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is H, alkyl or alkenyl; R2 is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl; R3 is optionally substituted phenyl, heteroaryl or naphthyl; R4 is H, alkyl, fluoro-alkyl, cyclopropylmethyl, —CH2CH2OH, —CH2CH2—O-alkyl, —CH2C(O)—O-alkyl, —CH2C(O)NH2, —CH2C(O)—NHalkyl or —CH2C(O)—N(alkyl)2; R19 is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; and R5, R13, R14, R15 and R16 are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译:使用下式的CCR5拮抗剂或其药学上可接受的盐,其中R是任选取代的苯基,吡啶基,噻吩基或萘基; R 1是H,烷基或烯基; R 2是任选取代的苯基,苯基烷基,杂芳基或杂芳基烷基,萘基,芴基或 二苯基甲基; R3是任选取代的苯基,杂芳基或萘基; R 4是H,烷基,氟代烷基,环丙基甲基,-CH 2 CH 2 OH,-CH 2 CH 2 -O-烷基,-CH 2 C(O)-O-烷基,-CH 2 C(O) ,-CH 2 C(O)-NH烷基或-CH 2 C(O)-N(烷基)2; R 19是任选取代的苯基,杂芳基或萘基,环烷基,环烷基烷基或烷氧基烷基; 和R 5,R 13,R 14,R 15和R 16是氢或烷基,用于治疗HIV,实体器官移植排斥,移植物抗宿主病,关节炎,类风湿性关节炎,炎性肠病,特应性皮炎,牛皮癣,哮喘,过敏或多发性硬化 以及新化合物,包含它们的药物组合物,以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。
摘要:
The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译:使用式5的CCR5拮抗剂或其药学上可接受的盐,其中R是任选取代的苯基,吡啶基,噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基,取代的杂芳基,萘基,芴基,二苯基甲基或任选取代的苯基 - R 4是氢或烷基; R 6是氢,烷基或链烯基; R 4是氢或烷基; R 3是氢,烷基或烷氧基烷基, 公开了用于治疗HIV,实体器官移植排斥,移植物抗宿主病,关节炎,类风湿性关节炎,炎症性肠病,特应性皮炎,牛皮癣,哮喘,过敏或多发性硬化的新型化合物,以及包含它们的药物组合物 ,以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。
摘要:
The present invention relates to certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “Fused Tricyclic Compounds”), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.
摘要:
The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient.
摘要:
The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.